The effect of Lactobacillus reuteri supplementation in Helicobacter pylori infection: a placebo-controlled, single-blind study

Abstract

Background: Helicobacter pylori is the major cause of chronic gastritis, and considered as a risk factor for peptic ulcer and gastric cancer. The H. pylori standard antibiotic therapy fails in about 25-30% of cases, particularly because of the increasing occurrence of resistance to antibiotics. The aim of the current study was to investigate whether the strain Lactobacillus reuteri DSM17648 which has been previously shown to reduce Helicobacter pylori load additionally improves gastrointestinal symptoms in H. pylori positive subjects when used in a 28 days supplementation. Methods: In a single-blinded, placebo controlled study 24 H. pylori-positive adults (13 females, 11 males; median age: 43.5) with mild dyspepsia (mean GSRS score: 11.82) received placebo for 28 days followed by Pylopass™ containing the L. reuteri DSM 17648 (2 × 10 10 cells per day) for the following 28 days. After 28 days of Pylopass™ supplementation the change in H. pylori load was measured by 13 C urea breath test (13 C-UBT) and the change in symptoms were determined by the Gastrointestinal Symptom Rating Scale (GSRS). In addition, blood assessments were conducted to measure the physiological changes relevant in terms of safety. Results: After a 28-day supplementation phase with Pylopass™ there was a trend for reduction of H. pylori load in 62.5% of the subjects and for the overall GSRS scores in 66.7% of subjects. The overall GSRS scores from baseline to day 56 following all 24 subjects undergoing the placebo phase followed by the Pylopass™ phase was significantly decreased (p = 0.005). The mean 13C-UBT δ value decreased by 22.5% during the Pylopass™ supplementation phase (− 3.14), while the mean 13C-UBT δ increased by 37.3% (+ 3.79) in the placebo phase. No side effects were reported in either study phase. Conclusion: The results demonstrated that L. reuteri DSM17648 has the potential to suppress H. pylori infection, and may lead to an improvement of H. pylori-associated gastro intestinal symptoms. Further studies with adequate power should be performed.

Paraprobiotics and Postbiotics of Probiotic Lactobacilli, Their Positive Effects on the Host and Action Mechanisms: A Review

“…Currently the application of postbiotics and paraprobiotics in human food, animal feed and pharmaceutical industries is increasing and several paraprobiotic and postbiotics products derived from Lactobacill species are commercially available for prevention or treatment of some diseases (221)(222)(223)(224)(225). Nevertheless, more evidence is needed to validate the beneficial effects of paraprobiotics and postbiotics.…”

Helicobacter pylori: Perturbation and restoration of gut microbiome

“…The strain DSM17648 co-aggregates the pathogen both in vivo and in vitro . A specific co-aggregation occurs between different strains of H. pylori and L. reuteri DSM17648 but not with Camylobacter jejuni or other intestinal and oral bacteria (Holz et al 2015 ; Buckley et al 2018 ).…”

Uso De Lactobacillus Na Erradicação De Helicobacter Pylori E Na Redução De Reações Adversas Ao Tratamento Convencional: Uma Revisão Integrativa

“…Os autores Paoluzi et al 26 relataram melhora de distúrbios do paladar, diarreia e inchaço. E, finalmente, os autores Buckley et al 27 demonstraram melhora somente na constipação (Quadro 3).…”

“…Enany; Abdalla 18 ; Shi et al 23 ; Poonyam et al 24 ; Yu et al 25 ; Paoluzi et al 26 Vômito (4 artigos) Abdalla 18 ; Lü et al 22 ; Enany; Shi et al 23 ; Poonyam et al 24 Constipação (3 artigos) Lü et al 22 ; Shi et al 23 ; Buckley et al 27 Diarreia (3 artigos) Lü et al 22 ;Shi et al 23 ; Paoluzi et al 26 Náusea (3 artigos) Enany; Abdalla 18 ; Shi et al 23 ; Poonyam et al 24 Distensão abdominal (1 artigo) Poonyam et al 24 Inchaço (1 artigo) Paoluzi et al 26 Quadro 2. Funções dos Lactobacilos utilizados como complemento conforme a dados obtidos.…”

“…Os probióticos sugiram como uma nova opção terapêutica para condições infecciosas 17 . Eles podem ser utilizados como monoterapia ou concomitante ao tratamento convencional 27 , desempenhando papel auxiliar contra infecção por H. pylori. Os microrganismos devem ter algumas características para serem enquadrados como probióticos, além da sobrevivência e viabilidade quando forem consumidos em alimentos 29 .…”